Bipartisan bill revealed to lower drug prices in US
The Senate Finance Committee has unveiled its bipartisan bill in an effort to lower drug prices, requiring drug manufacturers to justify price increases.
List view / Grid view
The Senate Finance Committee has unveiled its bipartisan bill in an effort to lower drug prices, requiring drug manufacturers to justify price increases.
FDA issues warning to a company that claimed its CBD products can be used to treat cancer and Alzheimer's disease.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
The global downstream processing market is predicted to witness record-breaking growth due to a surge in the adoption of biotech processes.
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
The FDA and EMA have agreed to rely on each other’s assessment of pharmaceutical manufacturing sites to reduce duplicative work.
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
Pharmaceutical packaging in China has increased at a rate of 10 percent in recent years and is predicted to continue high growth.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
The rise of diseases such as inflammatory bowel syndrome is projected to drive the global gastrointestinal drugs market in the upcoming years.
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.